Further research indicated that this SE is unique to this leukemia subtype, that an ETO2-GLIS2 fusion can activate the SE and that the SE can coregulate two tyrosine kinase genes in a signaling pathway that controls the progression of leukemia [52]. The gene discussed is GLIS2; the disease is leukemia.